These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
291 related articles for article (PubMed ID: 20405969)
1. The cost of relapse for patients with a manic/mixed episode of bipolar disorder in the EMBLEM study. Hong J; Reed C; Novick D; Haro JM; Windmeijer F; Knapp M Pharmacoeconomics; 2010; 28(7):555-66. PubMed ID: 20405969 [TBL] [Abstract][Full Text] [Related]
2. The cost of relapse in patients with schizophrenia in the European SOHO (Schizophrenia Outpatient Health Outcomes) study. Hong J; Windmeijer F; Novick D; Haro JM; Brown J Prog Neuropsychopharmacol Biol Psychiatry; 2009 Aug; 33(5):835-41. PubMed ID: 19351551 [TBL] [Abstract][Full Text] [Related]
3. The cost-effectiveness of lamotrigine in the maintenance treatment of adults with bipolar I disorder. Calvert NW; Burch SP; Fu AZ; Reeves P; Thompson TR J Manag Care Pharm; 2006 May; 12(4):322-30. PubMed ID: 16792438 [TBL] [Abstract][Full Text] [Related]
4. Clinical and economic consequences of medication non-adherence in the treatment of patients with a manic/mixed episode of bipolar disorder: results from the European Mania in Bipolar Longitudinal Evaluation of Medication (EMBLEM) study. Hong J; Reed C; Novick D; Haro JM; Aguado J Psychiatry Res; 2011 Nov; 190(1):110-4. PubMed ID: 21571375 [TBL] [Abstract][Full Text] [Related]
5. A systematic review and economic model of the clinical effectiveness and cost-effectiveness of interventions for preventing relapse in people with bipolar disorder. Soares-Weiser K; Bravo Vergel Y; Beynon S; Dunn G; Barbieri M; Duffy S; Geddes J; Gilbody S; Palmer S; Woolacott N Health Technol Assess; 2007 Oct; 11(39):iii-iv, ix-206. PubMed ID: 17903393 [TBL] [Abstract][Full Text] [Related]
7. Why do clinicians maintain antidepressants in some patients with acute mania? Hints from the European Mania in Bipolar Longitudinal Evaluation of Medication (EMBLEM), a large naturalistic study. Rosa AR; Cruz N; Franco C; Haro JM; Bertsch J; Reed C; Aarre TF; Sanchez-Moreno J; Vieta E J Clin Psychiatry; 2010 Aug; 71(8):1000-6. PubMed ID: 20361912 [TBL] [Abstract][Full Text] [Related]
8. Economic evaluation of hospital at home versus hospital care: cost minimisation analysis of data from randomised controlled trial. Jones J; Wilson A; Parker H; Wynn A; Jagger C; Spiers N; Parker G BMJ; 1999 Dec; 319(7224):1547-50. PubMed ID: 10591720 [TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of asenapine in the treatment of bipolar I disorder patients with mixed episodes. Sawyer L; Azorin JM; Chang S; Rinciog C; Guiraud-Diawara A; Marre C; Hansen K J Med Econ; 2014 Jul; 17(7):508-19. PubMed ID: 24720805 [TBL] [Abstract][Full Text] [Related]
10. Annual cost of bipolar disorder to UK society. Das Gupta R; Guest JF Br J Psychiatry; 2002 Mar; 180():227-33. PubMed ID: 11872515 [TBL] [Abstract][Full Text] [Related]
11. Cost effectiveness of olanzapine in prevention of affective episodes in bipolar disorder in the United Kingdom. McKendrick J; Cerri KH; Lloyd A; D'Ausilio A; Dando S; Chinn C J Psychopharmacol; 2007 Aug; 21(6):588-96. PubMed ID: 17050661 [TBL] [Abstract][Full Text] [Related]
12. Intravenous magnesium sulphate and sotalol for prevention of atrial fibrillation after coronary artery bypass surgery: a systematic review and economic evaluation. Shepherd J; Jones J; Frampton GK; Tanajewski L; Turner D; Price A Health Technol Assess; 2008 Jun; 12(28):iii-iv, ix-95. PubMed ID: 18547499 [TBL] [Abstract][Full Text] [Related]
13. Costs associated with attempted suicide among individuals with bipolar disorder. Stensland MD; Zhu B; Ascher-Svanum H; Ball DE J Ment Health Policy Econ; 2010 Jun; 13(2):87-92. PubMed ID: 20919595 [TBL] [Abstract][Full Text] [Related]
14. The real world cost and health resource utilization associated to manic episodes: The MANACOR study. Hidalgo-Mazzei D; Undurraga J; Reinares M; Bonnín Cdel M; Sáez C; Mur M; Nieto E; Vieta E Rev Psiquiatr Salud Ment; 2015; 8(2):55-64. PubMed ID: 25752959 [TBL] [Abstract][Full Text] [Related]
15. Cost-utility analysis of treatment with olanzapine compared with other antipsychotic treatments in patients with schizophrenia in the pan-European SOHO study. Knapp M; Windmeijer F; Brown J; Kontodimas S; Tzivelekis S; Haro JM; Ratcliffe M; Hong J; Novick D; Pharmacoeconomics; 2008; 26(4):341-58. PubMed ID: 18370568 [TBL] [Abstract][Full Text] [Related]
16. Health care resource utilization and costs in a commercially insured population of patients with bipolar disorder type I and frequent psychiatric interventions. Bagalman E; Muser E; Choi JC; Durden E; Macfadden W; Haskins JT; Dirani R Clin Ther; 2011 Oct; 33(10):1381-1390.e4. PubMed ID: 22000656 [TBL] [Abstract][Full Text] [Related]
17. A systematic review of the clinical effectiveness and cost-effectiveness and economic modelling of minimal incision total hip replacement approaches in the management of arthritic disease of the hip. de Verteuil R; Imamura M; Zhu S; Glazener C; Fraser C; Munro N; Hutchison J; Grant A; Coyle D; Coyle K; Vale L Health Technol Assess; 2008 Jun; 12(26):iii-iv, ix-223. PubMed ID: 18513467 [TBL] [Abstract][Full Text] [Related]
18. A 6-month, multicenter, open-label evaluation of beaded, extended-release carbamazepine capsule monotherapy in bipolar disorder patients with manic or mixed episodes. Ketter TA; Kalali AH; Weisler RH; J Clin Psychiatry; 2004 May; 65(5):668-73. PubMed ID: 15163253 [TBL] [Abstract][Full Text] [Related]
19. [Management of patients with acute manic or mixed episodes and outcome at three months]. Azorin JM; Luquiens A; Aubrun E; Reed C; Gasquet I; Lukasiewicz M Encephale; 2010 Jun; 36(3):226-35. PubMed ID: 20620265 [TBL] [Abstract][Full Text] [Related]
20. Predictors of switching from mania to depression in a large observational study across Europe (EMBLEM). Vieta E; Angst J; Reed C; Bertsch J; Haro JM; J Affect Disord; 2009 Nov; 118(1-3):118-23. PubMed ID: 19269690 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]